You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.



World Hemophilia Day 2021, Kedrion alongside patients

Today, more than ever, the company is close to those who are in a vulnerable condition

read more 


Rh&Life, first subject included in the study

Two hundred pregnant women to be enrolled over five countries

read more 


KIDCARES10, first patient enrolled in pediatric PI study

Thirty patients aged 2 to 17 years old to be enrolled over five European countries

read more 
  1. PLASMA & BIOTHERAPIES - 11-01-2021

    CARES10 clinical trial: last patient treated in the USA

    Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients

    read more 
  2. CORPORATE - 22-12-2020

    A chat with Val Romberg

    Kedrion Biopharma's new CEO shares his views

    read more 
  3. EVENTS - 16-12-2020

    Turkey, Kedrion supports the XVII International Congress on Hemophilia

    The present and future role of Factor VIII at the center of the symposium supported by Kedrion

    read more 
  4. EVENTS - 05-11-2020

    Kedrion is one of the main sponsors of the National SISET Conference

    The company sponsors two scientific lectures, a testament to its close ties with the world of medicine and science

    read more 


For more information please contact: [email protected]